D. Parker

发表

Ibrexafungerp: an orally active β-1,3-glucan synthesis inhibitor.

P. Liberator, M. Motyl, M. Peel, 2020, Bioorganic & medicinal chemistry letters.

MK-5204: An orally active β-1,3-glucan synthesis inhibitor.

P. Liberator, M. Motyl, M. Peel, 2020, Bioorganic & medicinal chemistry letters.

Development of a novel tricyclic class of potent and selective FIXa inhibitors.

J. Metzger, R. Berger, Hong Li, 2015, Bioorganic & medicinal chemistry letters.

Microenvironment mapping via Dexter energy transfer on immune cells

R. Oslund, C. White, E. Hett, 2020, Science.

Discovery and development of benzo-[1,2,4]-triazolo-[1,4]-oxazepine GPR142 agonists for the treatment of diabetes.

F. Ujjainwalla, E. Sherer, R. Nargund, 2016, Bioorganic & medicinal chemistry letters.

Triazolo-tetrahydrofluorenones as selective estrogen receptor beta agonists.

S. Nilsson, A. Thorsell, L. Colwell, 2006, Bioorganic & medicinal chemistry letters.

Macrocycle Formation by Catalytic Intramolecular Cyclopropanation. A New General Methodology for the Synthesis of Macrolides

V. Lynch, M. Doyle, D. Parker, 1997 .

Formation of Macrocyclic Lactones by Enantioselective Intramolecular Cyclopropanation of Diazoacetates Catalyzed by Chiral CuI and RhII Compounds

M. Doyle, D. Parker, C. S. Peterson, 1996 .

Synthesis of α,β-disubstituted cycloalkenones through a sequence of olefin metathesis and oxidative rearrangement

D. Parker, D. Meng, 2002 .

μMap-Red: Proximity Labeling by Red Light Photocatalysis.

G. Scholes, Daniel G. Oblinsky, A. Ploss, 2022, Journal of the American Chemical Society.

Discovery and Optimization of a Novel Triazole Series of GPR142 Agonists for the Treatment of Type 2 Diabetes.

F. Ujjainwalla, E. Sherer, A. Howard, 2016, ACS medicinal chemistry letters.

Small molecule photocatalysis enables drug target identification via energy transfer

R. Oslund, C. White, P. Tawa, 2021, bioRxiv.

Cyp1 Inhibition Prevents Doxorubicin‐Induced Cardiomyopathy in a Zebrafish Heart‐Failure Model

Peter S. Kutchukian, D. Johns, R. Peterson, 2020, Chembiochem : a European journal of chemical biology.

Rapid development of two factor IXa inhibitors from hit to lead.

W. Greenlee, R. Berger, E. Sherer, 2015, Bioorganic & medicinal chemistry letters.

Synthesis and biological evaluation of antifungal derivatives of enfumafungin as orally bioavailable inhibitors of β-1,3-glucan synthase.

P. Liberator, G. J. Pacofsky, M. Peel, 2012, Bioorganic & medicinal chemistry letters.

Use of fluoroalkyl as a latent group for internal alkylation: application to the synthesis of bridged tetrahydrofluorenones.

D. Parker, D. Meng, M. Greenlee, 2008, Organic letters.

Development of a novel class of potent and selective FIXa inhibitors.

E. Sherer, K. Ellsworth, W. Geissler, 2015, Bioorganic & medicinal chemistry letters.

Tandem [4 + 2]/[3 + 2] Cycloadditions of Nitroalkenes. 12. Synthesis of (-)-Platynecine.

S. Denmark, D. Parker, J. Dixon, 1997, The Journal of organic chemistry.

μMap Photoproximity Labeling Enables Small Molecule Binding Site Mapping.

R. Oslund, C. White, Keun Ah Ryu, 2023, Journal of the American Chemical Society.

Synthesis and properties of 2-(naphthosultamyl)methyl-carbapenems with potent anti-MRSA activity: discovery of L-786,392.

J. Heck, S. T. Waddell, R. Wilkening, 1999, Bioorganic & medicinal chemistry letters.